Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies

Targeted kinase inhibitors and camptothecins have shown preclinical and clinical activity in several cancers. This trial evaluated the maximum tolerated dose (MTD) and dose‐limiting toxicities of sorafenib and topotecan administered orally in pediatric patients with relapsed solid tumors. Sorafenib...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Reed, Damon R., Mascarenhas, Leo, Manning, Kathleen, Hale, Gregory A., Goldberg, John, Gill, Jonathan, Sandler, Eric, Isakoff, Michael S., Smith, Tiffany, Caracciolo, Jamie, Lush, Richard M., Juan, Tzu‐Hua, Lee, Jae K., Neuger, Anthony M., Sullivan, Daniel M.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2015
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4735769/
https://ncbi.nlm.nih.gov/pubmed/26714427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.598
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars